Skip to main content
OpenTrials
Completed

NCT Number: NCT07291752

The Risk of Second Primary Gastrointestinal Malignancies Following Primary Gastrointestinal Carcinoid Tumors: a SEER Based Study 2000-2022

Carcinoid tumors are rare neuroendocrine tumors with slowly progressive course. Carcinoid tumors are the most common gastrointestinal (GI) neuroendocrine tumors. The most common sites of GI carcinoids are small intestine accounting for 45%, rectum (20%), appendix (17%), colon (11%), and stomach (7%). Some studies reported an association between neuroendocrine tumors and multiple malignancies. However, the presence of neuroendocrine tumors combined with multiple primary GI tumors is considered an exotic event in the literature with only few case studies and case series. So the aim of this study is to assess the risk of GI malignancies following primary GI carcinoids.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Carcinoid Tumor Adenocarcinoma Carcinoma Neoplasms Neoplasms by Histologic Type Neoplasms, Germ Cell and Embryonal Neoplasms, Glandular and Epithelial Neoplasms, Nerve Tissue Neoplasms, Second Primary Neuroectodermal Tumors Neuroendocrine Tumors Second Primary Malignant Neoplasm

Sex eligibility

All sexes

Study type

Observational

About this study

Carcinoid tumors are rare neuroendocrine tumors with slowly progressive course. Carcinoid tumors are the most common gastrointestinal (GI) neuroendocrine tumors. The most common sites of GI carcinoids are small intestine accounting for 45%, rectum (20%), appendix (17%), colon (11%), and stomach (7%). Some studies reported an association between neuroendocrine tumors and multiple malignancies. However, the presence of neuroendocrine tumors combined with multiple primary GI tumors is considered an exotic event in the literature with only few case studies and case series. So the aim of this study is to assess the risk of GI malignancies following primary GI carcinoids.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • patients diagnosed with gastrointestinal carcinoid tumor.
  • patients diagnosed from 2000 till 2022

Exclusion criteria

  • patients diagnosed with autopsy only or death certificate only.
  • patients lacking age documentation.

Treatment and study plan

Primary outcomes

  1. The standardized incidence ratio and excess risk of second primary gastrointestinal malignancies following primary gastrointestinal carcinoid tumors

    Time frame: Jan, 2000 till Dec, 2022

    The surveillance, epidemiology and End Results (SEER) database was used to calculate the standardized incidence ratio (SIR) as Observed/Expected (O/E) and calculated the excess risk for second primary gastrointestinal malignancies following primary gastrointestinal carcinoid tumors

  2. The standardized incidence ratio and excess risk of gastrointestinal second primary malignancies stratified according to the primary gastrointestinal carcinoids site.

    Time frame: from Jan, 2000 till Dec, 2022

Sponsors and collaborators

Lead sponsor

Suez Canal University

Other

Registry information

Important dates

Study start
2000
Primary completion
2022
Study completion
2022
First posted
Dec 18, 2025
Registry last updated
Dec 18, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.